Axoltis Pharma receives authorization to launch SEALS - phase II clinical trial for ALS patients with drug candidate NX210c menafn.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from menafn.com Daily Mail and Mail on Sunday newspapers.